Petrin Dino, Baker Adam, Coupland Stuart G, Liston Peter, Narang Monica, Damji Karim, Leonard Brian, Chiodo Vince A, Timmers Adrian, Hauswirth William, Korneluk Robert G, Tsilfidis Catherine
Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.
Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2757-63. doi: 10.1167/iovs.02-0729.
To evaluate the neuroprotective effects of adenoassociated virus delivery of XIAP in N-methyl-N-nitrosourea (MNU)-induced retinal degeneration in Sprague-Dawley rats.
Sprague-Dawley rats were injected subretinally with recombinant adenoassociated virus (rAAV) encoding either XIAP or green fluorescent protein (GFP; injection control). Six weeks after injection, the animals received an intraperitoneal injection of MNU, a DNA methylating agent, at a dose of 60 mg/kg. Electroretinograms (ERGs) were recorded at 0, 24, 48 and 72 hours and 1 week after MNU. The rats were killed after the ERG was performed and were perfused with 4% paraformaldehyde. Eyes were then enucleated and embedded for cryosectioning. Eye sections were analyzed by TUNEL and histologic techniques. Real-time PCR and Western analysis were performed to confirm the overexpression of XIAP in injected eyes.
Real-time PCR and Western analysis confirmed the overexpression of XIAP in virus-injected eyes in comparison to uninjected control eyes. At 24 hours after MNU injection, fewer cells had undergone apoptosis in the XIAP-treated eyes in comparison with GFP-injected or uninjected eyes. Hematoxylin and eosin staining revealed that the uninjected and GFP-injected photoreceptors were destroyed by 72 hours after injection of MNU, whereas the AAV-XIAP-injected eyes showed structural protection of the photoreceptors at all time points throughout the 1-week sampling period. ERGs showed functional protection up to 1 week after MNU injection in the AAV-XIAP-injected eye, whereas no response was observed in the control eye.
The results suggest that XIAP is protective against this potent chemotoxic agent and holds promise as a therapeutic agent in gene therapy approaches to treating retinitis pigmentosa.
评估腺相关病毒介导X染色体连锁凋亡抑制蛋白(XIAP)对N-甲基-N-亚硝基脲(MNU)诱导的Sprague-Dawley大鼠视网膜变性的神经保护作用。
将编码XIAP或绿色荧光蛋白(GFP;注射对照)的重组腺相关病毒(rAAV)经视网膜下注射到Sprague-Dawley大鼠体内。注射六周后,动物腹腔注射剂量为60 mg/kg的DNA甲基化剂MNU。在MNU注射后0、24、48和72小时以及1周时记录视网膜电图(ERG)。在进行ERG检查后处死大鼠,并用4%多聚甲醛灌注。然后摘除眼球并包埋用于冷冻切片。通过TUNEL和组织学技术分析眼组织切片。进行实时聚合酶链反应(PCR)和蛋白质免疫印迹分析以证实注射眼中XIAP的过表达。
实时PCR和蛋白质免疫印迹分析证实,与未注射对照眼相比,病毒注射眼中XIAP过表达。在MNU注射后24小时,与注射GFP或未注射的眼睛相比,XIAP处理的眼睛中发生凋亡的细胞较少。苏木精-伊红染色显示,未注射和注射GFP的光感受器在注射MNU后72小时被破坏,而注射AAV-XIAP的眼睛在整个1周采样期的所有时间点均显示光感受器的结构得到保护。ERG显示,在注射AAV-XIAP的眼睛中,MNU注射后长达1周有功能保护,而对照眼中未观察到反应。
结果表明,XIAP对这种强效化学毒性剂具有保护作用,有望作为治疗色素性视网膜炎的基因治疗方法中的治疗剂。